255 related articles for article (PubMed ID: 26910291)
1. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
Feng Y; Wang Y; Zhu Z; Li W; Sussman RT; Randall M; Bosse KR; Maris JM; Dimitrov DS
MAbs; 2016; 8(4):799-810. PubMed ID: 26910291
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
5. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
6. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
Wood AC; Maris JM; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Wu J; Kurmasheva RT; Whiteman K; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Nov; 60(11):1860-7. PubMed ID: 23798344
[TBL] [Abstract][Full Text] [Related]
7. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
[TBL] [Abstract][Full Text] [Related]
8. Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models.
Yu L; Yao Y; Wang Y; Zhou S; Lai Q; Lu Y; Liu Y; Zhang R; Wang R; Liu C; Gou L; Chen X; Yu Y; Chen Q; Yang J
J Drug Target; 2018 Dec; 26(10):905-912. PubMed ID: 29630426
[TBL] [Abstract][Full Text] [Related]
9. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
[TBL] [Abstract][Full Text] [Related]
10. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
11. Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.
Ho ECH; Qiu R; Miller E; Bilotta MT; FitzGerald D; Antignani A
Biomed Pharmacother; 2023 Jan; 157():114047. PubMed ID: 36459711
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
13. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R
Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
[TBL] [Abstract][Full Text] [Related]
16. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
17. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
Crossland DL; Denning WL; Ang S; Olivares S; Mi T; Switzer K; Singh H; Huls H; Gold KS; Glisson BS; Cooper LJ; Heymach JV
Oncogene; 2018 Jul; 37(27):3686-3697. PubMed ID: 29622795
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
